Partner, Birch & Lake Bio
Analysis · April 2026
Everyone knows that drug costs are high, but can they also be too low? In a seeming paradox, concerned observers are saying yes. Despite growing evidence that patients face undue risk, changing the status quo remains difficult for politicians and healthcare leaders alike.
Interview · November 2026
Jeremy Levin believes drugmakers owe a duty to the public, not just shareholders. In an interview with Henri Mattila, the seasoned executive and entrepreneur says Washington should take a page from Beijing’s strategic playbook if it wants the United States to remain a leader in medical innovation.
Interview · December 2024
On the harder path of biotech investing, why medicines endure, and what actually bottlenecks AI in drug discovery.
Interview · December 2024
How a philanthropy shapes health policy without advocating for it, and where affordability and transparency go next.
Interview · May 2024
A leader at the intersection of technology and healthcare on the promise and peril of social media, artificial intelligence, and the misinformation that travels faster than the facts.
Interview · February 2024
On growing up amid war, why healthcare has no equivalent of a nutrition label, and what it would take to hand the money back to the people who already pay for it.
Interview · September 2022
For all the attention paid to America’s fading competitiveness in a globalized economy, there is one sector where the United States still reigns supreme.
Stay informed